Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.72 |
| ▸ | POLA1 | P09884 | 2/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | F2 | P00734 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30372497 | 1.00 | MEN1 (0.73) | MEN1KMT2AKCNH2POLA1TP53 | |
| SCHEMBL6696197 | 0.97 | MEN1 (0.70) | MEN1KMT2AKCNH2POLA1TP53 | |
| SCHEMBL6694423 | 0.90 | MEN1 (0.60) | MEN1KMT2AKCNH2POLA1TP53 | |
| SCHEMBL6815376 | 0.89 | MEN1 (0.61) | MEN1KMT2AKCNH2POLA1TP53 | |
| SCHEMBL6703046 | 0.88 | KCNH2 (0.61) | MEN1KMT2AKCNH2POLA1TP53 | |
| SCHEMBL6694408 | 0.88 | KCNH2 (0.61) | MEN1KMT2AKCNH2POLA1TP53 | |
| SCHEMBL6709492 | 0.88 | KCNH2 (0.61) | MEN1KMT2AKCNH2POLA1TP53 | |
| SCHEMBL6697470 | 0.88 | KCNH2 (0.61) | MEN1KMT2AKCNH2POLA1TP53 | |
| SCHEMBL6698352 | 0.88 | F2 (0.62) | MEN1KMT2AKCNH2POLA1TP53 | |
| SCHEMBL6697171 | 0.87 | MEN1 (0.59) | MEN1KMT2AKCNH2POLA1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160346287-A1 | METHOD OF TREATING VIRAL INFECTIONS | EPIPHANY BIOSCIENCES, INC. | 2016-12-01 | — | — | US | claimed |
| US-20150050241-A1 | METHOD OF TREATING VIRAL INFECTIONS | EPIPHANY BIOSCIENCES, INC. | 2015-02-19 | — | — | US | claimed |
| WO-2014047562-A2 | METHOD OF TREATING AND/OR PREVENTING SHINGLES AND METHOD OF TREATING AND/OR PREVENTING ZOSTER ASSOCIATED PAIN | EPIPHANY BIOSCIENCES (US) | 2014-03-27 | — | — | WO | claimed |
| US-20040186131-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-09-23 | — | — | US | claimed |
| EP-1140851-B1 | 4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | UPJOHN CO (US) | 2004-09-01 | — | — | EP | claimed |
| EP-1140851-A1 | 4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-10-10 | — | — | EP | claimed |
| US-6248736-B1 | DNA POLYMERASE INHIBITORS EFFECTIVE AGAINST HERPESVIRUSES | PHARMACIA & UPJOHN COMPANY | 2001-06-19 | — | — | US | claimed |
| WO-2000040563-A1 | 4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-13 | — | — | WO | claimed |
| US-20210186977-A1 | MEDICAL USES | XNK Therapeutics AB (SE) | 2021-06-24 | — | — | US | disclosed |
| EP-3787685-A1 | MEDICAL USES | XNK Therapeutics AB (SE) | 2021-03-10 | — | — | EP | disclosed |
| US-20160346287-A1 | METHOD OF TREATING VIRAL INFECTIONS | EPIPHANY BIOSCIENCES, INC. | 2016-12-01 | — | — | US | disclosed |
| US-20150050241-A1 | METHOD OF TREATING VIRAL INFECTIONS | EPIPHANY BIOSCIENCES, INC. | 2015-02-19 | — | — | US | disclosed |
| WO-2014047562-A2 | METHOD OF TREATING AND/OR PREVENTING SHINGLES AND METHOD OF TREATING AND/OR PREVENTING ZOSTER ASSOCIATED PAIN | EPIPHANY BIOSCIENCES (US) | 2014-03-27 | — | — | WO | disclosed |
| US-20040186131-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-09-23 | — | — | US | disclosed |
| EP-1140851-B1 | 4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | UPJOHN CO (US) | 2004-09-01 | — | — | EP | disclosed |
| EP-1140851-A1 | 4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6248736-B1 | DNA POLYMERASE INHIBITORS EFFECTIVE AGAINST HERPESVIRUSES | PHARMACIA & UPJOHN COMPANY | 2001-06-19 | — | — | US | disclosed |
| WO-2000040563-A1 | 4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346287-A1 | METHOD OF TREATING VIRAL INFECTIONS | IFNG, BCL9, GDA | MEN1 74/4885KMT2A 1025/4885KCNH2 3322/4885 |
| US-20150050241-A1 | METHOD OF TREATING VIRAL INFECTIONS | IFNG, BCL9, GDA | MEN1 74/4885KMT2A 1025/4885KCNH2 3322/4885 |
| US-20040186131-A1 | Method of preventing or treating atherosclerosis or restenosis | LDLR, NR1H3, NR1H2 | MEN1 3030/4885KMT2A 4688/4885KCNH2 4383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.